Sertraline alters multidrug resistance phosphoglycoprotein activity in the mouse placenta and fetal blood-brain barrier

Reproductive Sciences

Volumn 19, Issue 4, 2012, Pages 407-415

  Bhuiyan, Manzerul ^a   Petropoulos, Sophie ^a   Gibb, William ^b   Matthews, Stephen G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

3H digoxin; brain; multidrug resistance phosphoglycoprotein; placenta; sertraline

Indexed keywords

MULTIDRUG RESISTANCE PHOSPHOGLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; SERTRALINE; UNCLASSIFIED DRUG;

AMNION FLUID; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CIRCULATION; CONTROLLED STUDY; DIFFUSION; DRUG TRANSPORT; FEMALE; FETUS; MALE; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DETERMINATION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DIGOXIN; FEMALE; FETUS; MALE; MANNITOL; MICE; P-GLYCOPROTEIN; PLACENTA; PREGNANCY; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 84859917093     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111424438     Document Type: Article

References (49)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-162.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84(21):7735-7738.
3. Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989;9(3):1346-1350. (Pubitemid 19071705)
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427. (Pubitemid 23237876)
5. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stagespecific distribution of P-glycoprotein in first-trimester and fullterm human placenta. J Histochem. 1994;26(5):417-423. (Pubitemid 24171685)
6. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27(6-7):602-609.
7. Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biol Reprod. 2005;73(4):591-597. (Pubitemid 41356116)
8. Mylona P, Hoyland JA, Sibley CP. Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression. Placenta. 1999;20(5-6):493-496. (Pubitemid 29301623)
9. Iqbal M, Gibb W, Matthews SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology. 2011;152(3):1067-1079.
10. van Kalken CK, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol. 1992;141(5):1063-1072.
11. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992;267(34):24248-24252.
12. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491-502. (Pubitemid 24153990)
13. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698-1705.
14. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104(10):1441-1447.
15. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3-29. (Pubitemid 36078452)
16. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. Pglycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468-7485.
17. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305(1):197-204. (Pubitemid 36373851)
18. Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64(20):7562-7569. (Pubitemid 39372101)
19. Argov M, Kashi R, Peer D, Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett. 2009;274(1):118-125.
20. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323(7307):257-260. (Pubitemid 32729111)
21. Petropoulos S, Kalabis GM, Gibb W, Matthews SG. Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone. Reprod Sci. 2007;14(4):321-328. (Pubitemid 351168812)
22. Petropoulos S, Gibb W, Matthews SG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res. 2010;1357:9-18.
23. Marken PA, Munro JS. Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Prim Care Companion J Clin Psychiatry. 2000;2(6):205-210.
24. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997;100(10):2430-2436. (Pubitemid 27514881)
25. Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173-181.
26. Bond H, Baker B, Boyd RD, et al. Artificial perfusion of the fetal circulation of the in situ mouse placenta: methodology and validation. Placenta. 2006;27(suppl A):S69-S75.
27. Coles LD, Lee IJ, Hassan HE, Eddington ND. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. J Pharm Sci. 2009;98(8):2832-2846.
28. Sibley CP, Coan PM, Ferguson-Smith AC, et al. Placental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci USA. 2004;101(21):8204-8208. (Pubitemid 38698078)
29. McClive PJ, Sinclair AH. Rapid DNA extraction and PCR-sexing of mouse embryos. Mol Reprod Dev. 2001;60(2):225-226. (Pubitemid 32847133)
30. Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006;237(2):180-187. (Pubitemid 43777079)
31. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol. 1996;16(3 suppl 2):37S-50S; discussion 50S-53S.
32. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147-153.
33. Achira M, Totsuka R, Fujimura H, Kume T. Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats. Eur J Pharm Sci. 2002;16(1-2):29-36. (Pubitemid 34756779)
34. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003;54(8):840-846. (Pubitemid 37205136)
35. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem. 1997;250(1):130-137. (Pubitemid 27504592)
36. Sterz K, Mollmann L, Jacobs A, Baumert D, Wiese M. Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. Chem Med Chem. 2009;4(11):1897-1911.
37. Dayan G, Jault JM, Baubichon-Cortay H, et al. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry. 1997;36(49):15208-15215. (Pubitemid 27527985)
38. Taylor JC, Ferry DR, Higgins CF, Callaghan R. The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br J Cancer. 1999;81(5):783-789. (Pubitemid 29504685)
39. Trezise AE, Romano PR, Gill DR, et al. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. J EMBO. 1992;11(12):4291-4303.
40. Yang CP, Cohen D, Greenberger LM, Hsu SI, Horwitz SB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem. 1990;265(18):10282-10288.
41. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol. 1990;10(4):1652-1663.
42. Kajiji S, Talbot F, Grizzuti K, et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry. 1993;32(16):4185-4194. (Pubitemid 23137723)
43. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry. 1995;34(1):32-39.
44. De las Cuevas C, Sanz EJ. Safety of selective serotonin reuptake inhibitors in pregnancy. Curr Drug Saf. 2006;1(1):17-24.
45. Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/ noradrenergic antidepressants during pregnancy: a review. Clin Ther. 2009;31(pt 1):1426-1453.
46. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372-2383. (Pubitemid 40676760)
47. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402-408. (Pubitemid 36521227)
48. Berlin I, Warot D, Legout V, Guillemant S, Schollnhammer G, Puech AJ. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther. 1998;63(4):428-436. (Pubitemid 28214966)
49. Raap DK, Evans S, Garcia F, et al. Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther. 1999;288(1):98-106. (Pubitemid 29113479)